We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases

By LabMedica International staff writers
Posted on 07 Jul 2025

The human body hosts trillions of bacteria, particularly in the gut, which have a significant role in digestion and various other aspects of health. More...

These gut bacteria produce a variety of metabolites that act as molecular messengers, influencing processes such as metabolism, immune function, brain activity, and mood. However, understanding the exact relationships between bacteria and the metabolites they produce is still in its infancy.

As gut bacteria are highly diverse and interact in complex ways, it’s challenging to pinpoint how these microbes influence human health and diseases. The difficulty in mapping these relationships hinders the development of targeted treatments. Researchers have been seeking methods to better understand the bacteria-metabolite interactions and how they can be applied in personalized treatments. Now, for the first time, researchers have used a special kind of artificial intelligence (AI) to probe a dataset on gut bacteria in order to find relationships that current analytical tools could not reliably identify.

The tool called VBayesMM has been developed by a team of researchers from the University of Tokyo (Tokyo, Japan) to help map the complex relationships between gut bacteria and metabolites. Using a Bayesian neural network, VBayesMM analyzes large datasets to identify key bacterial players affecting metabolite production. The system automatically distinguishes between the significant bacteria that influence metabolites and the vast background of less relevant microbes.

VBayesMM also accounts for uncertainty in the predictions, providing more accurate and reliable results compared to other existing methods. The tool has been tested on real data from studies on sleep disorders, obesity, and cancer, consistently outshining other techniques and uncovering bacterial families linked with known biological processes.

The findings, published in Nature Communications, show that the tool outperformed existing analytical methods by reliably identifying bacteria which align with biological processes and by acknowledging uncertainty in predictions. This approach gives researchers greater confidence in the results, reducing the risk of overconfident and potentially incorrect conclusions.

The tool offers promising applications in personalized healthcare, where it could help identify bacterial targets for treatments or dietary interventions. Moving forward, the researchers plan to enhance VBayesMM by incorporating more comprehensive chemical datasets and improving its robustness for diverse patient populations, ultimately transitioning from basic research to practical medical applications.

“The problem is that we’re only beginning to understand which bacteria produce which human metabolites and how these relationships change in different diseases,” said Project Researcher Tung Dang from the Tsunoda lab in the Department of Biological Sciences. “By accurately mapping these bacteria-chemical relationships, we could potentially develop personalized treatments. Imagine being able to grow a specific bacterium to produce beneficial human metabolites or designing targeted therapies that modify these metabolites to treat diseases.”

Related Links:
University of Tokyo


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Platelet Function Analyzer
PL-12
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.